Multiple Myeloma Coverage from Every Angle

Paul G. Richardson, MD, on a Novel Immunotherapy Plus Dexamethasone in Relapsed or Refractory Myeloma

Posted: Monday, July 13, 2020

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses a novel cereblon E3 ubiquitin ligase-modulating agent, CC-92480, combined with dexamethasone in a first-in-human phase I study of patients with relapsed or refractory myeloma. Overall responses were observed, even among heavily pretreated patients.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.